Translational Research Initiative for Hearing (TRIH) Grant aims to help strengthen the translation of fundamental research towards patient benefit
Expression of Interest deadline extended to 3 May 2016
Our Translational Research Initiative for Hearing (TRIH) Grant aims to help strengthen the translation of fundamental research towards patient benefit. It supports:
- Research with a strong commercial potential that is likely to attract follow-on funding at the conclusion of the grant.
- Studies that will facilitate and enable the progression of promising basic research towards testing in clinical trials.
The TRIH Grant does not support basic research into the causes and underpinning biology of hearing loss and tinnitus or the development of devices or software.
Summary of TRIH Grant 2016
- Duration: Up to three years
- Eligibility: Applicants may be from any country and may be from academic institutions and small/medium enterprises
- Value*: Up to £100,000 per year
– Extended Expression of Interest deadline: 3 May 2016 (5 pm GMT)
– Funding decisions: October 2016
* Please note that as a charity, it is our policy not to fund any indirect costs or the salaries of permanent employees.
An Expression of Interest must be submitted, using the form below. The purpose of the Expression of Interest is to obtain enough information on the proposed project to enable us to understand how well the proposal aligns with the “Requirements and eligibility” of the TRIH scheme. Applicants with proposals meeting the criteria of the scheme will be invited to submit a full application. Full details of the TRIH grant and the Expression of Interest form can be found below.
You can download download a free PDF viewer (external website, opens in new window) from the Adobe website, and a free Word viewer(external link, opens in new window)from the Microsoft website.
Requirements and eligibility
The scope of the TRIH call varies from year to year. This year, applications will be accepted in the following areas:
Small molecule, gene or cell-based approaches for the treatment of hearing loss or tinnitus. This can include:
- Studies which will enable lead optimisation and/ or candidate selection.
- Pharmacokinetic/Pharmacodynamic (PKPD) studies.
- Safety/toxicology studies.
- Drug repositioning/repurposing (applications must contain preliminary data supporting the proposed approach)
Research that addresses at least one of the following “TRIH Challenge” topics:
- Validation of therapeutic targets for the treatment of hearing loss or tinnitus (applications must contain preliminary data supporting the proposed approach).
- Studies to strengthen confidence that a target or therapeutic approach will be applicable to human hearing loss or tinnitus.
- Preclinical model validation i.e. studies to increase the understanding of in-vivo or in-vitro model relevance to human hearing loss or tinnitus.
- Identification/validation of methods or outcomes that could be used for one or more of the following:
- Patient selection/stratification for clinical trials
- Robust measurement of treatment responses in clinical trials
This year, applications will not be accepted in the following areas:
- Basic research into the causes and underpinning biology of hearing loss and tinnitus.
- Novel drug delivery to the ear.
- The development of devices or software
- The optimization of current clinical protocols
- Health service studies
All applications are sent to two/three external referees in the field who are asked to rate the scientific value, feasibility, and translational potential of the project. The applications and associated peer reviews are then assessed and rated by members of our TRIH funding review panel. The top-rated applications are then put forward for funding.
Applicants are notified of the outcome as soon as possible following the final decision. Feedback is provided to all applicants.
TRIH Funding Review Panel
- Dr Rick Cousins (GSK)
- Dr Paul England (InMedD)
- Dr Paul Fletcher (Leigh-Abbot Consulting Limited)
- Dr Jonathan Gale (University College London)
- Dr Fiona Marston (Sapere Systems Ltd)
- Professor Gerard O’Donoghue (Nottingham Hearing Biomedical Research Unit)
- Dr Marielle Portier (Otopharm)
- Professor Karen Steel (King’s College London)
- Dr Chris Watkins (Medical Research Council)
For more information
If you would like more information about the TRIH grant please contact:
Telephone: +44 (0)20 7294 3742